J. Axten

发表

Discovery of GSK2656157: An Optimized PERK Inhibitor Selected for Preclinical Development.

A. Hassell, R. Gampe, J. Axten, 2013, ACS medicinal chemistry letters.

Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.

S. Rabindran, N. Campobasso, V. Sudakin, 2011, Journal of medicinal chemistry.

Characterization of GSK 2334470 , a novel and highly specific inhibitor of PDK 1

D. Alessi, E. Sommer, J. Axten, 2010 .

Pharmacological targeting of the unfolded protein response for disease intervention

C. Hetz, J. Axten, J. Patterson, 2019, Nature Chemical Biology.

PERK inhibition delays neurodegeneration and improves motor function in a mouse model of Marinesco-Sjögren syndrome

M. Sallese, N. Laping, R. Chiesa, 2018, Human molecular genetics.

Rapid synthesis of diversely functionalized 3,4,7-trisubstituted indoles

T. Gallagher, J. Axten, Seth W. Grant, 2011 .

A highly selective, cell-permeable furin inhibitor BOS-318 rescues key features of cystic fibrosis airway disease.

K. Wilcoxen, N. Campobasso, J. Axten, 2022, Cell chemical biology.

Protein kinase R(PKR)–like endoplasmic reticulum kinase (PERK) inhibitors: a patent review (2010-2015)

J. Axten, 2017, Expert opinion on therapeutic patents.

Discovery of a new series of Aurora inhibitors through truncation of GSK1070916.

Ramona N Plant, M. A. Hardwicke, J. Axten, 2010, Bioorganic & medicinal chemistry letters.

Conversion of 2-deoxyglucose-induced growth inhibition to cell death in normoxic tumor cells

Rakesh Kumar, M. Kurtoğlu, T. Lampidis, 2013, Cancer Chemotherapy and Pharmacology.

TLR2 agonism reverses chemotherapy-induced neutropenia in Macaca fascicularis.

J. Foley, N. Laping, J. Cottom, 2017, Blood advances.

Novel amino-piperidines as potent antibacterials targeting bacterial type IIA topoisomerases.

S. Dabbs, D. Davies, T. Gallagher, 2011, Bioorganic & medicinal chemistry letters.

Neurodegeneration and Clinical Disease in Prion-Infected Mice Oral Treatment Targeting the Unfolded Protein Response Prevents

P. Fischer, D. Barrett, C. Ortori, 2013 .

A Stereoselective Synthesis of dl-threo-Methylphenidate: Preparation and Biological Evaluation of Novel Analogues†

H. Kung, J. Winkler, J. Axten, 1998 .

Enantioselective Synthesis of d-threo-Methylphenidate

J. Winkler, J. Axten, L. Krim, 1999 .

The First Total Syntheses of Ircinol A, Ircinal A, and Manzamines A and D.

J. Winkler, J. Axten, 1998, Journal of the American Chemical Society.

Stereoselective synthesis of the tetracyclic core of manzamine via the vinylogous amide photocycloaddition cascade

J. Winkler, U. Lengweiler, J. Axten, 1998 .

An ab initio molecular orbital study of the grignard reagents CH3MgCl and [CH3MgCl]2: The Schlenk equilibrium

J. Axten, C. Bock, M. Trachtman, 1994 .

Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK).

L. Shewchuk, S. Rabindran, A. Hassell, 2012, Journal of medicinal chemistry.

An Approach to the Synthesis of the Manzamine Alkaloids Via the Vinylogous Amide PHotocycloAddition/Retro‐Mannich Fragmentation/Mannich Closure Cascade (pharM)

M. Siegel, J. Winkler, J. Axten, 1997 .

Benzyl 2-cyano-3,3-dimethyl-1-pyrrolidinecarboxylate, a versatile intermediate for the synthesis of 3,3-dimethylproline derivatives.

K. Erhard, J. Axten, C. Blackledge, 2008, The Journal of organic chemistry.

An ab Initio Molecular Orbital Study of Small Magnesium Dihalide Clusters

J. Axten, C. Bock, M. Trachtman, 1994 .

Oral Treatment Targeting the Unfolded Protein Response Prevents Neurodegeneration and Clinical Disease in Prion-Infected Mice

P. Fischer, D. Barrett, C. Ortori, 2013, Science Translational Medicine.

Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity.

Brent M. Sanders, H. Alsaid, Rakesh Kumar, 2013, Cancer research.

Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1.

Ayaz Najafov, Dario R Alessi, D. Alessi, 2011, The Biochemical journal.

Targeting PERK signaling with the small molecule GSK2606414 prevents neurodegeneration in a model of Parkinson's disease

C. Hetz, S. Sardi, J. Hoozemans, 2018, Neurobiology of Disease.

Broad Kinase Inhibition Mitigates Early Neuronal Dysfunction in Tauopathy

N. Seyfried, D. Duong, D. Powell, 2021, International Journal of Molecular Sciences.

Broad kinase inhibition mitigates early neuronal dysfunction and cognitive deficits in tauopathy

N. Seyfried, D. Duong, D. Powell, 2020, bioRxiv.

Aminoindazole PDK1 Inhibitors: A Case Study in Fragment-Based Drug Discovery.

J. Briand, N. Campobasso, J. Axten, 2010, ACS medicinal chemistry letters.

Acylprolinamides: a new class of peptide deformylase inhibitors with in vivo antibacterial activity.

N. Campobasso, J. Axten, Seth W. Grant, 2012, Bioorganic & medicinal chemistry letters.

A mild and general method for the synthesis of 2-substituted-5-hydroxypyrimidines

J. Axten, J. Medina, T. A. Henry, 2006 .

A novel method for the 1,2-carbonyl transposition of pleuromutilins

T. Gallagher, J. Axten, C. Duquenne, 2010 .